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Introduction: Non-small cell lung cancer (NSCLC) is characterized
by a multitude of genetic aberrations with unknown clinical impact.
In this study, we aimed to identify gene copy number changes that
correlate with clinical outcome in NSCLC. To maximize the chance
to identify clinically relevant events, we applied a strategy involving
two prognostically extreme patient groups.
Methods: Short-term (20 month; n 53) and long-term survivors
(58 month; n  47) were selected from a clinically well-charac-
terized NSCLC patient cohort with available fresh frozen tumor
specimens. The samples were analyzed using high-resolution single-
nucleotide polymorphism array technology to assess gene copy number
variations and array-based gene expression profiling. The molecular
data were combined with information on clinical parameters.
Results: Genetic aberrations were strongly associated with tumor
histology. In adenocarcinoma (n  50), gene copy number gains on
chromosome 8q21-q24.3 (177 genes) were more frequent in long-
term than in short-term survivors. In squamous cell carcinoma (n 
28), gains on chromosome 14q23.1-24.3 (133 genes) were associ-
ated with shorter survival, whereas losses in a neighboring region,
14q31.1-32.33 (110 genes), correlated with favorable outcome. In
accordance with copy number gains and losses, messenger RNA
expression levels of corresponding genes were increased or de-
creased, respectively.
Conclusion: Comprehensive tumor profiling permits the integration
of genomic, histologic, and clinical data. We identified gene copy
number gains and losses, with corresponding changes in messenger
RNA levels that were associated with prognosis in adenocarcinoma
and squamous cell carcinoma of the lung.
Key Words: Lung cancer, Prognosis, SNP array, CGH, Gene
expression profile.
(J Thorac Oncol. 2011;6: 1833–1840)
Lung cancer is the leading cause of cancer-related deathworldwide.1 The risk of recurrence and development of
metastases is high even in early-stage patients treated with
surgery.2 The introduction of novel targeted therapies has
prolonged survival in subsets of patients with advanced lung
cancer.3–5 However, the overall poor prognosis warrants
novel strategies for risk stratification, therapy response pre-
diction, and development of new treatment options. Today,
the only molecular marker that guides treatment decisions in
patients with advanced non-small cell lung cancer (NSCLC)
is the epidermal growth factor receptor mutation status.3,6
Genome-wide high-resolution techniques, including
gene expression and genomic arrays, have been used to define
molecular subgroups associated with prognosis and response
to therapy. However, in NSCLC, the value of these molecular
signatures remains unclear in contrast to many other cancer
entities.7–10 This may, in part, be explained by the difficulty to
obtain fresh frozen tissue specimens, as only a small fraction
of patients with NSCLC undergo surgical treatment. There-
fore, most published series are small and many consist of
samples pooled from several cancer centers. In addition, the
histologic heterogeneity of NSCLC is high compared with
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that of most solid cancers, and if this translates into molecular
heterogeneity, relevant molecular signatures will be difficult
to find. Nevertheless, prognostic gene expression signatures
have been described for NSCLC cohorts composed of differ-
ent histologic subgroups.11 Another obstacle in many NSCLC
samples is the admixture of genetically normal nonmalignant
stromal and inflammatory cells, because of pneumonia and
scarring, which will dilute signals from acquired genetic
aberrations in the tumor cells.12–14
The aim of this study was to characterize genetic aberra-
tions in NSCLC. To maximize the chance to identify molecular
signatures independently connected to prognosis, two patient
populations with different survival outcomes were selected and
compared. Histologically well-characterized NSCLC tissue
samples were analyzed using high-resolution single-nucleotide
polymorphism (SNP) array technology to assess copy number
changes. In addition, array-based global gene expression profil-
ing was performed, and the molecular data were combined with
information on clinical parameters.
PATIENTS AND METHODS
Patient Selection
The Uppsala-O¨rebro Lung Cancer Registry is a clinical
audit and research database that includes details on diagnostic
procedures, tumor type, tumor stage, recommended treat-
ment, and performance status according to the World Health
Organization. The source population consisted of surgically
treated patients with primary NSCLC reported to the registry
from 1995 through 2005 with available fresh frozen NSCLC
tissue in the Uppsala Biobank at the Department of Pathol-
ogy. Patients with a history of other cancers or neo-adjuvant
treatment were excluded. All samples were used in accor-
dance with the Swedish Biobank Legislation (Uppsala Ethical
Review Board reference No. 2006/325). Patients were se-
lected at the Uppsala Regional Oncology Center independent
of the participating pathologists. All investigators (with the
exception of the study statistician) were blinded to patient
outcome throughout the laboratory analyses.
DNA and RNA Preparation
The fresh frozen NSCLC samples were embedded in
Tissue-tek OCT (Sakura Finetek USA, Torrance, CA) and
stored at80°C as previously described.15,16 A hematoxylin and
eosin-stained frozen section (4 m) was prepared from each
sample and examined by two pathologists (P.M. and J.B.).
Samples were included in the study if they were of adequate size
(5 mm) and contained representative NSCLC tissue with a
tumor cell fraction of at least 50% (viable tumor cells versus
viable normal epithelium, stromal, and inflammatory cells).
Samples with extensive necrosis were excluded. If necessary,
the sample blocks was macro-dissected (sectioned by knife at
semi-thawed state at 20°C) to produce a modified block with
higher tumor cell fraction and/or less necrosis. After cutting
sections for DNA and RNA isolation, a final hematoxylin and
eosin-stained frozen section was morphologically examined to
confirm that the sample histology was unchanged.
DNA and RNA were extracted from 2 to 10 frozen
tissue sections (10 m) using the QIAamp DNA Mini Kit
(Qiagen, Hilden, Germany) and the RNeasy Mini Kit (Qia-
gen), respectively. DNA and RNA concentrations were mea-
sured with a ND-1000 spectrophotometer (NanoDrop Tech-
nologies, Wilmington, DE), and the RNA quality (RNA
Integrity Number [RIN], www.agilent.com/chem/RIN) was
assessed by the Agilent 2100 Bioanalyzer system (Agilent
Biotechnologies, Palo Alto, CA).
Microarray SNP Analysis of Gene Copy
Number Variations
Array experiments were performed according to the
standard protocols for Affymetrix GeneChip Mapping 250K
Nsp I arrays (Gene Chip Mapping 500K Assay Manual, P/N
701930 Rev2., Affymetrix Inc., Santa Clara, CA). Quality
control, genotype calling, and probe-level normalization were
performed using the Affymetrix GeneChip Genotyping Anal-
ysis Software (GTYPE) 4.1. The Dynamic Model algorithm
was used to perform single sample quality control and geno-
type calls. Copy number normalization, to produce log(2)
ratios, was performed using the Copy Number Analysis Tool
4.0.1. The reference set was 82 normal samples of white
origin analyzed at the Uppsala Array Platform. Subsequent
copy number analyses and group comparisons were per-
formed using the software BioDiscovery Nexus Copy Num-
ber 3.0 (El Segundo, CA) and the built-in Rank Segmentation
algorithm for estimating copy numbers and segmenting each
interval. The significance threshold for segmentation was set
to 1  106, and the log(2) ratio threshold, of a minimum of
30 probes in a row, was defined as more than 0.15 or less than
0.15 for gains or losses, respectively. The mean probe
distance was approximately 10 kb. Thus, the length of the
regions with the minimum number of 30 probes was 300 kb
on average. Gene copy number changes with a frequency
difference of more than 30% between the two survival groups
were compared with a two-tailed Fisher’s exact test (p  0.05).
Regions close to centromeres and telomeres were discarded
from further analysis as constitutional gene copy number vari-
ants are overrepresented in these regions.17 Focal regions of
genetic aberrations with a statistically significant higher fre-
quency of copy number changes over the “background” level
(35%) were identified using the Nexus implementation of the
global frequency statistic approach, the Significance Testing for
Aberrant Copy number method (BioDiscovery Nexus Copy
Number 3.0).
Validation of Copy Number Changes Using
Quantitative Real-Time Polymerase Chain
Reaction
To validate copy number alterations identified on chro-
mosome 8 for adenocarcinoma and on chromosome 14 for
squamous cell carcinoma, quantitative real-time polymerase
chain reaction (PCR) was performed in triplicate reactions on
DNA from matched samples (tumor and normal lung from
the same patient) using the Maxima SYBR Green qPCR
Master Mix (Fermentas, St Leon-Rot, Germany). Primers for
quantitative PCR were designed to amplify regions on chro-
mosomes 8 and 14 using the Primer 3 software. In addition,
primers amplifying internal control regions with normal copy
number according to SNP array data were designed for
Micke et al. Journal of Thoracic Oncology • Volume 6, Number 11, November 2011
Copyright © 2011 by the International Association for the Study of Lung Cancer1834
adenocarcinoma and squamous cell carcinoma, respectively
(primer sequences available upon request). DNA copy num-
bers for tumor samples were normalized against the copy
number neutral internal control regions and ratios relative to
DNA copy number from the matched normal samples were
calculated for each locus.
Microarray Gene Expression Analysis
A total of 2 g RNA (RIN value 7.0) from each
tissue specimen was used for analysis on Affymetrix Human
Genome U133 plus 2 arrays (Affymetrix Inc.). Sample prep-
aration, processing, and hybridization were performed ac-
cording to the GeneChip Expression Analysis Technical
Manual (Affymetrix Inc., Rev. 5). Subsequent analyses of the
gene expression data were carried out in the freely available
statistical computing language R (http://www.r-project.org)
using packages available from the Bioconductor project.18
The raw data were normalized using the robust multiarray
average method19 and has been uploaded together with
clinical information on GEO with the accession number
GSE28582 (www.ncbi.nlm.nih.gov/geo/). Only transcripts
with average signal intensities above 5 were used for further
analysis. For comparison of gene expression levels between
different patient groups, a two-sided Student’s t test was used.
Validation of Microarray Gene Expression Data
Using Quantitative Real-Time PCR
For validation of gene expression levels obtained by
microarray analysis, primers for three genes on chromosome
8q21-q24.3 (block of proliferation [BOP1]), 14q23.1-24.3
(LTBP2), and 14q31.1-32.33 (modulator of apoptosis 1
[MOAP1]) were designed using the freely available Primer 3
software (primer sequences available upon request). Patient
samples were selected based on gene expression array data to
represent different gene expression levels in adenocarcinoma
(n 9) and squamous cell carcinoma subtypes (n 11). cDNA
was synthesized from 1 g of RNA using the High Capacity
RNA-to-cDNA Kit (Applied Biosystems, Foster City, CA) ac-
cording to the manufacturer’s protocol. The quantitative real-
time PCR was performed as previously described.16
Statistics
To correlate clinical variables and lung cancer survival,
2 and Fisher’s exact tests were used. The Wilcoxon two-
sample test was used to test difference between survival and
age at diagnosis. The associations between survival (dichot-
omized into short- and long-term survival) and other clinical
parameters were evaluated by univariate and multivariate
binary logistic regression models. For each model, odds ratios
and 95% confidence intervals are given. The multivariate
logistic regression models were adjusted for gender, age,
tumor stage, and performance status according to the World
Health Organization criteria. To obtain the Pearson correla-
tion between log ratio of gene copy number changes and
messenger RNA (mRNA) expression, the statistical software
R was used. Knowing the start and stop positions of the genes,
corresponding log ratios of gene copy numbers were retrieved
from the segment files generated by the Nexus software. In cases
where the gene regions encompassed more than one segment,
the segment containing the start position of the gene was se-
lected. To calculate the Pearson correlation coefficient (2 ), the
existing R function cor was applied. Moreover, the lm function
was used to fit a linear model and thus retrieve the slope (k) of
the relation between mRNA expression and log ratio. For genes
with multiple probes on the array, average correlation and
gradient values were calculated. All analyses were performed
using the statistical software R.
RESULTS
Study Design
The selection strategy was designed to maximize the
power to identify molecular events that correlate with clinical
outcome. The source population of surgically treated patients
with NSCLC reported to the Uppsala-O¨rebro Lung Cancer
Registry 1995–2005 comprised 382 cases with available fresh
frozen tumor tissue. Inclusion in the study was based on: (1)
NSCLC histology of squamous cell carcinoma, adenocarci-
noma, or large-cell carcinoma; (2) tumor sample size more
than 5 mm; (3) tumor cell fraction more than 50% in the fresh
frozen tissue sample, as evaluated by pathologists and con-
firmed by an unbiased method based on SNP array data13; and
(4) RNA quality (RIN7.0). In total, 202 tissue samples met
the inclusion criteria. These cases were ranked according to
survival time, and 100 patients were selected based on overall
survival, approximately pairwise one from the beginning and
one from the end of the list, to represent short-term (range
0–20 months; n  53) and long-term survivors (range 58–
172 months; n  47). This selection resulted in a relatively
similar distribution of clinical and histopathologic parameters
between the two groups. As expected, there was a tendency
that short-term survivors were slightly older, more often men,
more often of large-cell carcinoma histology, and had a
higher tumor stage than long-term survivors, although the
only statistically significant difference was a higher propor-
tion of patients with low performance status in the short-term
survival group (Tables 1 and 2).
Because the large-cell carcinoma subgroup was small,
disproportionally balanced between long- and short-term sur-
vivors (n  8 and n  14, respectively), and represents a
heterogeneous mixture of histologic NSCLC subtypes, the
study was further focused on the adenocarcinoma and squa-
mous cell carcinoma subgroups.
Gene Copy Number Analysis
Initially, the overall frequency of genetic aberrations in
the complete cohort composed of all histologic subtypes (n
100) was evaluated (Figure 1). Large regions (5 Mb) with
recurrent aberrations (30%) include amplification on 1q,
3q, 5p, and 8q, and deletion on 3p, 8p, 9p, and 13q.
A comparison of the two histologic subgroups of squa-
mous cell carcinoma and adenocarcinoma revealed clear
differences in the frequency of genomic aberrations. Large
aberrations (5 Mb) were more common in squamous cell
carcinoma than in adenocarcinoma (30% difference in the
frequency of aberrations) and included gene copy number
gains on chromosome 2p, 3q, 8p, and 20p and losses on 3p,
4p, 4q, 5q, 9p, 10q, 13q, and 17p. In contrast, gains on
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chromosome 1q were more abundant in adenocarcinoma
samples. The gene copy number profile of large-cell carcino-
mas revealed features of both adenocarcinoma and squamous
cell carcinoma. In addition, recurrent focal gene copy number
variations deviating from the “background” level of aberra-
tions were determined. In adenocarcinoma, six regions on
chromosome 1 and 8, in total encompassing 424 genes, were
identified. In squamous cell carcinoma, four regions on chro-
mosome 2, 8, and 17, including altogether 90 genes, were
determined (Supplementary Table 1, Supplemental Digital
Content 1, http://links.lww.com/JTO/A118).
Gene Copy Number and Survival
To identify genetic aberrations associated with sur-
vival, the frequency of gene copy number gains and losses
was compared between the two prognostic patient groups. In
the complete cohort (n  100) including all histologic sub-
groups, no chromosomal region exhibited a more than 30%
frequency difference between long- and short-term survivors
with regard to either amplifications or deletions.
The subgroup analysis of adenocarcinoma samples
(n  50) revealed regions on chromosome 8q21-q24.3 that
were more frequently amplified in long-term than in short-
term survivors (42–54% versus 12–23%), encompassing 177
genes (Figure 2, Supplementary Table 2a–b, Supplemental
Digital Content 2, http://links.lww.com/JTO/A119). In squa-
mous cell carcinoma (n  28), gains on chromosome 14
(q23.1–24.3, 139 genes) were associated with shorter survival
(31 versus 0%; Figure 3, Supplementary Table 2a, 2c, Supple-
mental Digital Content 2, http://links.lww.com/JTO/A119). In
contrast, gene copy number losses in a neighboring region
on chromosome 14 (q31.1–32.33, 110 genes) correlated
with favorable outcome (33% versus 0%; Figure 3, Sup-
plementary Table 2a, 2d, Supplemental Digital Content 2,
http://links.lww.com/JTO/A119). Interestingly, considering
the region 14q23.1-32.33 at large, gains were in general more
frequent in the short-term survivor group and losses more
frequent in the long-term survivor group at each analyzed
SNP locus (Figure 3).
We performed quantitative real-time PCR to validate
the copy number alterations identified in the survival-related
regions in adenocarcinoma and squamous cell carcinoma in
two representative cases with available normal tissue.
Matched DNA from tumor and normal tissue was analyzed
for one patient with adenocarcinoma with gain on chromo-
some 8 (8q21-q24.3) and one patient with squamous cell
carcinoma with loss on chromosome 14 (14q31.1-32.33).
Comparison of DNA copy number ratios from the quantitative
PCR analysis revealed gain and loss, respectively, in concor-
dance with the SNP array data (Supplementary Figure 1, Sup-
plemental Digital Content 3, http://links.lww.com/JTO/A120).
Gene Copy Number Changes and Gene
Expression
To strengthen our findings, we performed global mi-
croarray expression analysis on the 50 adenocarcinoma and
28 squamous cell carcinoma cases to evaluate if the gene
copy number changes were translated into changes in mRNA
expression levels.
TABLE 2. Univariate and Multivariate Logistic Regression
Models Were Applied to Analyze Associations of
Histopathologic and Clinical Characteristics with Long-Term
Survival in Patients with NSCLC (n  100)
Univariate Multivariate
OR 95% CI OR 95% CI
Gender
Male 1.00a 1.00a
Female 1.25 (0.57–2.75) 1.47 (0.56–3.88)
Age (yr)
60 1.00a 1.00a
60 0.77 (0.32–1.82) 0.58 (0.21–1.62)
Stage
IA–IIB 1.00a 1.00a
IIIA–IV 0.53 (0.18–1.54) 0.36 (0.11–1.12)
Histology
Adenocarcinoma 1.00a 1.00a
Large cell 0.62 (0.22–1.74) 0.65 (0.20–2.11)
Squamous cell 1.25 (0.49–3.16) 2.01 (0.65–6.24)
Performance status
PS 0 1.00a 1.00a
PS 1–4 0.26 (0.11–0.64) 0.22 (0.09–0.58)
a Set to 1.00 for reference.
OR, odds ratio; CI, confidence interval; PS, performance status.
TABLE 1. Characteristics of Patients from the Uppsala-
Örebro Lung Cancer Registry with Available Tumor Tissue
after Surgery Selected to Create Two Groups of Short- and
Long-Term Survivors
Short-Term
Survivors
(n  53), n (%)
Long-Term
Survivors
(n  47), n (%) p (2)
Gender 0.688
Men 30 (57) 24 (51)
Women 23 (43) 23 (49)
Age, median (range), yr 66 (40–80) 63 (44–82) 0.857
Survival, median (range), mo 9 (0–20) 107 (58–172) —
Smoking history 0.991
Never smoker 4 (8) 3 (6)
Ex-smoker 22 (42) 20 (43)
Current smoker 25 (47) 22 (47)
Missing 2 (3) 2 (4)
Tumour stage 0.285
IA–IIB 40 (75) 38 (81)
IIIA–IV 12 (23) 6 (13)
Missing 1 (2) 3 (6)
WHO performance status 0.001
PS 0 22 (45) 34 (76)
PS 1–4 27 (55) 11 (24)
Histology 0.506
Adenocarcinoma 26 (49) 24 (51)
Large-cell carcinoma 14 (26) 8 (17)
Squamous cell carcinoma 13 (25) 15 (32)
WHO, World Health Organization; PS, performance status.
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In adenocarcinomas, the identified region on chromosome
8q21-q24.3 was represented by 128 transcripts on the gene
expression chip. In accordance with the gene copy number
gains, the expression levels for 55 of the 128 genes (43%) were
significantly higher (amplified versus nonamplified cases;
p 0.05, two-sided t test; Supplementary Table 3a, Supplemen-
tal Digital Content 4, http://links.lww.com/JTO/A121). Only
four genes revealed lower expression levels (3%), all of
them with low absolute signal intensities. The remaining
65 genes did not show a significant difference in transcript
levels between amplified and nonamplified cases. In addi-
tion, the Pearson correlation was calculated between the
expression data and normalized log-ratio copy number data
from the SNP arrays for all annotated genes on chromosome
8q21-q24.3, with 85% of the genes showing a positive cor-
relation (Supplementary Table 3a, Supplemental Digital Con-
tent 4, http://links.lww.com/JTO/A121). Quantitative real-
time PCR for one gene in the region 8q21-q24.3 (BOP1,
8q24.3) was performed to support the gene expression array
results. There was a strong correlation (r  0.7) between the
two methods (Supplementary Figure 2, Supplemental Digital
Content 5, http://links.lww.com/JTO/A122).
In squamous cell carcinomas, 45 of 112 (40%) genes
showed significantly higher expression levels in association
with genomic gains in the survival region on chromosome
14q23.1–24.3 (amplified versus nonamplified cases; p  0.05,
two-sided t test; Supplementary Table 3b, Supplemental Digital
Content 4, http://links.lww.com/JTO/A121). In parallel with the
gene copy number loss on 14q31.1-32.33, expression levels of
26 of 82 genes (32%) were significantly lower in cases with loss
compared with cases without loss (p  0.05, two-sided t test;
Supplementary Table 3c, Supplemental Digital Content 4,
http://links.lww.com/JTO/A121). The remaining genes showed
only nonsignificant differences.
Because the two regions on chromosome 14 are in
proximity, aberrations often encompass parts of both regions
(14q23.1–24.3 and 14q31.1–32.33). Therefore, this region
was also analyzed as a whole. In total, 13 of the 28 squamous
cell cancer samples (46%) revealed genomic changes in this
region; five samples showed gene copy number loss, six
samples showed genomic gain, and two samples exhibited
both gains and losses in different parts of the region. The
comparison of mRNA expression levels between genes with
gain and loss revealed 104 of 194 genes (53%) that showed
corresponding significant expression differences (p  0.05,
two-sided t test; Supplementary Table 3d, Supplemental Dig-
ital Content 4, http://links.lww.com/JTO/A121). As expected,
the correlation coefficient between gene expression and gene
copy numbers was positive or negative for regions with genomic
gain and loss, respectively (Supplementary Table 3b–d, Supple-
mental Digital Content 4, http://links.lww.com/JTO/A121).
Two genes in the two survival regions 14q23.1-24.3
(LTBP2, 14q24.3) and 14q31.1-32.33 (MOAP1, 14q32.12)
were selected for quantitative real-time PCR analysis. The
correlation between the gene expression array and PCR
results was positive, r  0.9 and r  0.7, respectively
FIGURE 1. Global gene copy number analysis of 100 NSCLC cases using Affymetrix GeneChip 250K SNP arrays. Frequencies of
gene copy number gains (green) and losses (red) for all 100 samples and for the 50 adenocarcinomas, 22 large-cell carcinomas,
and 28 squamous cell carcinomas separately. NSCLC, non-small cell lung cancer; SNP, single-nucleotide polymorphism.
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(Supplementary Figure 2, Supplemental Digital Content 5,
http://links.lww.com/JTO/A122).
DISCUSSION
In this study, two patient groups with different survival
time were compared. We describe distinct gene copy number
gains and losses that were associated with prognosis in the
histologic subgroups of adenocarcinoma and squamous cell
carcinoma.
Several considerations increase the strength of this
study. All frozen samples originated from the same source
population and were stringently reviewed by pathologists.
The clinical parameters were obtained from a registry that
compiles data prospectively with high completeness and
without loss of follow-up. The selection of patients with
maximum survival discordance produced two populations
with a marked survival difference (median 9 versus 115
months) and increased the power to detect prognostic markers
even in an intrinsically heterogeneous study cohort. The
combined evaluation of different molecular aberrations—
global gene copy number analysis and gene expression—was
performed on high-quality RNA and DNA extracted from the
same tissue block, providing a comprehensive profile for each
patient. Several interesting observations provide intriguing
leads for further more focused studies. Nevertheless, this
study is based on a relatively small sample size, and there-
fore, we regard the results reported in this study as explor-
atory. The observation that mRNA levels correlate with the
gene copy number alterations supports the relevance of the
identified survival regions. Not unexpectedly, the correlation
was strong (r  0.7) only in a fraction of the genes, and
several genes showed only week or no correlation. This can
be explained by the fact that many of genes are not expressed
at all, or at very low levels in lung cancer tissue and that gains
and losses are not always translated into corresponding
mRNA transcript levels.
Array-based methods are powerful tools to characterize
genome-wide gene copy number alterations and are now
widely used in cancer research. Most previous lung cancer
studies comprise relatively small patient cohorts and mainly
adenocarcinoma specimens.20–23 One previous large-scale
study by Weir et al.9 include a set of 528 adenocarcinoma
specimens, but because of stromal cell contamination, only
371 tissue specimens were finally analyzed. These 371 sam-
ples were then further subdivided in tertiles based on the
amplitude of copy number variations. Comparing the results
from the top tertile to the adenocarcinoma cases in our study,
the frequencies of large scale and focal events are similar,
suggesting that we analyzed representative cases with a high
tumor cell fraction. No survival data were presented in the
study by Weir et al.9 A recent study24 evaluated 232 lung
cancer specimens for genetic alterations. They identified the
fibroblast growth factor receptor 1 (FGFR1 on chr8p11.22) as
frequently amplified in squamous cell carcinomas and sug-
FIGURE 2. Global gene copy number analysis of 50 adeno-
carcinoma cases using Affymetrix GeneChip 250K SNP arrays.
Comparison plot contrasting patients with long (58 months)
versus short (20 months) survival time. Gains on chromo-
some 8q were more frequent in patients with long-term sur-
vival than in patients with short time survival. The region
8q21-24.3 comprises 177 genes. SNP, single-nucleotide poly-
morphism.
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gested FGFR1 as a potential drug target based on additional
in vitro studies. No survival data were included in this study.
Interestingly, we could confirm the genomic region harboring
the FGFR1 as a recurrent focal amplification in squamous
carcinoma (Supplementary Table 1). No obvious correlation
with survival was seen in our data set.
Two previous studies have correlated genomic imbal-
ances with survival in lung adenocarcinoma. Shibata et al.21
evaluated 55 adenocarcinoma samples with a custom-made
comparative genomic hybridization array. The results indi-
cated loss of 13q14.1 and gain of 8q24.2 to be associated with
disease-free survival. This is in accordance with our data
(Figure 2), although only gain on chromosome 8 reached the
defined significance level in our study. More recently, another
study by Iwakawa et al.25 describe recurrent 8q24.21 ampli-
fication in 65 early-stage adenocarcinomas of the lung. They
showed that amplification of MYC—a known oncogene on
chr8q24.21—was associated with poor prognosis. Although
the frequency of gains was in accordance to our results, this
study indicated poor prognosis in patients with gain in re-
gions on chromosome 8q21-q24.3 in contrast to our findings.
Clearly, larger patient cohorts are needed to address the
relevance of chromosome 8 amplification.
In squamous cell carcinoma, the prognostic impact of
copy number gains on 14q23.1-24.3 and losses on 14q31.1-
32.33 represent novel findings. The overall high frequency of
aberrations on 14q23.1-32.33 (46% of squamous cell carci-
noma) and the surprisingly divergent genomic pattern in this
region, with gains in short-term and losses in long-term
survivors, may also indicate different underlying tumorigenic
mechanisms. The presence of complex loss-and-gain patterns
on the long arm of chromosome 14 (chr14q13.3) has also
been described by Harris et al.26 in a cohort of 45 NSCLC
cases. We identified similar changes in 14q13.3 (squamous
cell cancer; gain 14% and loss 11%), but no significant
association with survival.
Beyond prognostic information, the identified regions
might include genes of biological relevance for lung cancer
development. One candidate gene, BOP1 (chromosome
8q24.3, Supplementary Table 2a, 2b), was frequently ampli-
fied (36%) and exhibited higher expression levels (p  0.01,
two-sided t test) in long-term survivors in the adenocarci-
noma subgroup. BOP1 is involved in rRNA processing,
ribosome formation, and is linked to chromosomal instabil-
ity.27 Recently, BOP1 amplification and mRNA overexpres-
sion were described in colorectal cancer.28,29
MOAP1 (or MAP-1) is an interesting gene present in
the survival region on chromosome 14q32.12 in squamous
cell carcinoma (Supplementary Table 2a, 2d). This protein
contains a Bcl-2 homology 3-like motif, and its association
with BAX induces apoptosis. MOAP1-deficient cells show
anchorage-independent cell growth.30,31
Our results can be regarded as a proof of principle that
gene copy number changes are able to provide prognostic
FIGURE 3. Global gene copy number analysis of 28 squa-
mous cell carcinoma cases using Affymetrix GeneChip 250K
SNP arrays. Comparison plot contrasting patients with long
(58 months) versus short (20 months) survival time. Ge-
netic gains on chromosome 14q23.1-24.3 were associated
with shorter survival: (139 genes) and losses on 14q31.1-32.33
(110 genes; frequency 0% versus 33%) with favorable out-
come. SNP, single-nucleotide polymorphism.
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information beyond well-established clinical parameters. For
clinical diagnostics this is advantageous, as somatic genetic
alterations are relatively robust and tumor cell specific in
contrast to mRNA expression patterns.32,33 In addition, the
molecular stability of DNA and the possibility to extract
DNA from paraffin-embedded tumor material make genome-
wide copy number analysis a promising diagnostic tool in
molecular pathology. This study illustrates the emerging
possibilities of integrated evaluation of array-based molecular
data and clinical and histologic information. Genetic aberra-
tions were strongly associated with tumor histology, and we
identified novel gene copy number gains and losses associ-
ated with survival in adenocarcinoma and squamous cell
carcinoma of the lung.
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